Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma

Annals of Hematology

Volumn 89, Issue 3, 2010, Pages 273-282

  Fridrik, Michael A ^a   Hausmaninger, Hubert ^b   Lang, Alois ^c   Drach, Johannes ^d   Krieger, Otto ^e   Geissler, Dietmar ^f   Michlmayr, Gerhard ^e   Ulsperger, Ernst ^e   Chott, Andreas ^d   Oberaigner, Wilhelm ^g   Grei, Richard ^b  

^a KEPLER UNIVERSITY HOSPITAL   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c Landeskrankenhaus Feldkirch   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e Department Internal Medicine 1 ^*  (Austria)

^f GENERAL HOSPITAL KLAGENFURT   (Austria)

^g Institute for Clinical Epidemiology of the TILAK   (Austria)

Author keywords

Aggressive non Hodgkin lymphoma; Diffuse large B cell lymphoma; Dose dense; Treatment

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINATE CALCIUM; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; FEMALE; HAIR LOSS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; STOMATITIS; TREATMENT RESPONSE; ADOLESCENT; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FEMALE; FILGRASTIM; HUMANS; IFOSFAMIDE; INFECTION; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; PROGNOSIS; SURVIVAL RATE; VINCRISTINE; YOUNG ADULT;

EID: 77949314337     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0811-x     Document Type: Article

References (25)

1. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994. doi:10.1056/ NEJM199309303291402
2. Bertini M, Freilone R, Botto B, Calvi R, Gallamini A, Gatti AM, Liberati AM, Meneghini V, Orlandi E, Orsucci L, Pizzuti M, Scalabrini DR, Salvi F, Todeschini G, Vitolo U, Resegotti L (1997) Idarubicin in patients with diffuse large cell lymphomas: a randomized trial comparing VACOP-B (A=doxorubicin) vs VICOP-B (I=idarubicin). Haematologica 82:309-313
3. Carde P, Meerwaldt JH, van Glabbeke M, Somers R, Monconduit M, Thomas J, de Wolf-Peeters C, de Pauw B, Tanguy A, Kluin- Nelemans JC, Noordijk EM, Regnier R, Bron D, Lustinan- Marechal J, Caillou B, Bosq J, van Heerde P, van Unnik JAM, Burgers JMV, Hayat M, Cosset JM, Evd S, Wagener J, Hagenbeek A, Cattan A, Duez N, Tubiana M, on behalf of the ELG (1991) Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high-grade Non- Hodgkin's Lymphoma (NHL): The 1980-1985 EORTC trial. Ann Oncol 2:431-435
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 17:1244
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242. doi:10.1056/NEJMoa011795 (Pubitemid 34438862)
6. Cox DL (1972) Regression models an life tables. J Roy Statist Soc Ser B Methodological 34:187
7. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC (1975) Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1:248-250. doi:10.1016/ S0140-6736(75)91142-91143
8. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006. doi:10.1056/NEJM199304083281404 (Pubitemid 23095683)
9. Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr (1987) Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol 24:21-25
10. Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stoger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T (1997) Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy Ann Hematol 75:135-140
11. Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W (2005) Long-term results of dose density therapy in patients with aggressive lymphoma. Ann Hematol 84:217-222. doi:10.1007/s00277-004- 0936-x (Pubitemid 40425066)
12. Fridrik MA, Hausmaninger H, Linkesch W, Stoger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T (1996) CEOPIMVP- Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. J Clin Oncol 14:227-232
13. Goldie JH, Coldman AJ, Ng V, Hopkins HA, Looney WB (1988) A mathematical and computer-based model of alternating chemotherapy and radiation therapy in experimental neoplasms. Antibiot Chemother 41:11-20
14. Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma-results of a comprehensive metaanalysis. Cancer Treat Rev 33:338-346. doi:10.1016/j. ctrv.2007.02.002
15. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large bcell lymphoma. J Clin Oncol 24:3121-3127
16. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:547-581. doi:10.2307/2281868
17. Kimby E, Brandt L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol 40:198-212. doi:10.1080/ 02841860151116268 (Pubitemid 32588121)
18. Linch DC, Smith P, Hancock BW, Hoskin PJ, Cunningham DC, Newland AC, Milligan D, Stevenson PA, Wood JK, Maclennan KA, Vaughan B, Vaughan G, Gregory WM (2000) A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma. Ann Oncol 11(Suppl 1):87-90. doi:10.1023/A:1008381811131
19. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau J-L, the Groupe Ouest-Est des Leucemies et des Autres Maladies du S (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287-1295. doi:10.1056/NEJMoa031770
20. Norton L, Simon R (1977) Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 58:1735-1741
21. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116. doi:10.1016/S1470-2045(08)70002-0
22. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, German High-Grade Non- Hodgkin's Lymphoma Study G (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641 (Pubitemid 38970554)
23. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez- Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT). Group Lancet Oncol 7:379-391. doi:10.1016/S1470-2045(06)70664-7
24. Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, Morel P, Ferme C, Bosly A, Lederlin P, Laurent G, Tilly H (2005) ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205. doi:10.1056/ NEJMoa042040
25. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284-4289. doi:10.1182 blood-2003-02-0542